Journal article
Development, synthesis and biological investigation of a novel class of potent PC-PLC inhibitors
LI Pilkington, K Sparrow, SWP Rees, EK Paulin, M van Rensburg, CS Xu, RJ Langley, IKH Leung, J Reynisson, E Leung, D Barker
European Journal of Medicinal Chemistry | ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER | Published : 2020
Abstract
Phospholipases are enzymes that are involved in the hydrolysis of acyl and phosphate esters of phospholipids, generating secondary messengers that have implications in various cellular processes including proliferation, differentiation and motility. As such inhibitors of phospholipases have been widely studied for their use as anti-cancer therapeutics. Phosphatidylcholine-specific phospholipase C (PC-PLC) is implicated in the progression of a number of cancer cell lines including aggressing triple-negative breast cancers. Most current studies on PC-PLC have utilised D609 as the standard inhibitor however it is known to have multiple failings, including poor stability in aqueous media. 2-Morp..
View full abstractGrants
Awarded by Health Research Council of New Zealand
Funding Acknowledgements
We are very grateful for the financial support from the Cancer Society of New Zealand (Ref: 17.01) and the Breast Cancer Partnership, Health Research Council, New Zealand (Ref: 17/671).